Adalvo announces the DCP approval for Macitentan 10mg film-coated tablets, marking progress in expanding access to essential treatments for pulmonary arterial hypertension (PAH).
This product is based on the reference brand Opsumit, which generated $1.65 billion globally in 2023, with a 3-year CAGR of +5% (IQVIA).
Beyond Europe, we have also submitted the dossier in additional territories, positioning Adalvo as a global partner in the PAH sector.
Adalvo further highlights its position in PAH care with a comprehensive portfolio, including Riociguat and the Ambrisentan + Tadalafil fixed-dose combination, offering a range of treatment options tailored to patient needs.
Join us in shaping the future of healthcare. For collaboration opportunities, contact our Global Business Development team.
Partner with Us Today